Oncomatryx Biopharma SL (Oncomatryx) is a developer of precision drugs. The company offers precision drugs that targets proteins located in the tumor environment. It develops therapeutic antibody-drug conjugates, antibodies, and human-derived proteins, which targets tumor associated stroma. Oncomatryx's products comprise DMTX invaScan, DMTX bladderScan, DMTX breastScan, and companion diagnostics, among others. The company offers sensitive and specific monoclonal antibodies for the diagnosis of invasive carcinomas, among others. It markets its products through a network of distributors in Spain and abroad. Oncomatryx is headquartered in Derio, Spain.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope
Reasons to buy
Note: Some sections may be missing if data is unavailable for the company
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Oncomatryx Biopharma SL
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to buy
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Oncomatryx Biopharma SL Company Overview
- Oncomatryx Biopharma SL Company Snapshot
- Oncomatryx Biopharma SL Pipeline Products and Ongoing Clinical Trials Overview
- Oncomatryx Biopharma SL - Pipeline Analysis Overview
- Oncomatryx Biopharma SL - Key Facts
- Oncomatryx Biopharma SL - Major Products and Services
- Oncomatryx Biopharma SL Pipeline Products by Development Stage
- Oncomatryx Biopharma SL Pipeline Products Overview
- ELISA-Based Companion Diagnostic Kit - MTX3
- ELISA-Based Companion Diagnostic Kit - MTX3 Product Overview
- ELISA-Based Companion Diagnostic Kit - MTX5
- ELISA-Based Companion Diagnostic Kit - MTX5 Product Overview
- Immunohistochemistry Based Companion Diagnostic Kit - MTX3
- Immunohistochemistry Based Companion Diagnostic Kit - MTX3 Product Overview
- Immunohistochemistry Based Companion Diagnostic Kit - MTX5
- Immunohistochemistry Based Companion Diagnostic Kit - MTX5 Product Overview
- Oncomatryx Biopharma SL - Key Competitors
- Oncomatryx Biopharma SL - Key Employees
- Oncomatryx Biopharma SL - Locations And Subsidiaries
- Head Office
- Recent Developments
- Oncomatryx Biopharma SL, Recent Developments
- Mar 04, 2013: Oncomatrix Launches New Immunohistochemistry Kit To Diagnose And Prognose Tumor Invasiveness
- Appendix
- Methodology
- About
- Contact
- Disclaimer
List of Tables
- Oncomatryx Biopharma SL Pipeline Products and Ongoing Clinical Trials Overview
- Oncomatryx Biopharma SL Pipeline Products by Equipment Type
- Oncomatryx Biopharma SL Pipeline Products by Indication
- Oncomatryx Biopharma SL, Key Facts
- Oncomatryx Biopharma SL, Major Products and Services
- Oncomatryx Biopharma SL Number of Pipeline Products by Development Stage
- Oncomatryx Biopharma SL Pipeline Products Summary by Development Stage
- ELISA-Based Companion Diagnostic Kit - MTX3 - Product Status
- ELISA-Based Companion Diagnostic Kit - MTX3 - Product Description
- ELISA-Based Companion Diagnostic Kit - MTX5 - Product Status
- ELISA-Based Companion Diagnostic Kit - MTX5 - Product Description
- Immunohistochemistry Based Companion Diagnostic Kit - MTX3 - Product Status
- Immunohistochemistry Based Companion Diagnostic Kit - MTX3 - Product Description
- Immunohistochemistry Based Companion Diagnostic Kit - MTX5 - Product Status
- Immunohistochemistry Based Companion Diagnostic Kit - MTX5 - Product Description
- Oncomatryx Biopharma SL, Key Employees
- Glossary
List of Figures
- Oncomatryx Biopharma SL Pipeline Products by Equipment Type
- Oncomatryx Biopharma SL Pipeline Products by Development Stage
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Spanish Breast Cancer Research Group
- Multidisplinary Group on Digestive Cancer
- Curaxys SL
- Dynamic Solutions
